Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07011667

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants will either get CagriSema (a study medicine) or placebo (a dummy medicine that looks like CagriSema but has no active ingredient). Which treatment participants get is decided by chance. Participants are two times more likely to get CagriSema than placebo. If participants get CagriSema in the main study, participants will continue on CagriSema in the extension study. Which dose of CagriSema participants will continue on is decided by chance. If participants get placebo in the main study, participants will get CagriSema in the extension study. Participants will take one injection of study medicine once a week. The study will last for about 3 years and 3 months.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Obesity Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

FDRC, Costa Mesa, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

key Inclusion Criteria:

  • Male or female (sex at birth).
  • Age 18 years or above at the time of signing the informed consent.
  • BMI ≥ 30.0 kilogram per square meter (kg/m^2) at screening.
  • Participant has a wish to lose at least 25% of body weight within 80 weeks from randomisation.

key Exclusion Criteria:

  • Glycated haemoglobin (HbA1c) ≥ 6.5% (48 millimole per mole [mmol/mol]) as measured by the central laboratory at screening.
  • History of type 1 or type 2 diabetes.

Treatment and study plan

CagriSema (Cagrilintide B and Semaglutide I)

Drug

CagriSema (Cagrilintide B and Semaglutide I) will be administered subcutaneously using DV3384 pen-injector.

Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)

Drug

Placebo matched to Cagrilintide B and placebo matched to Semaglutide I will be administered subcutaneously using DV3384 pen-injector.

Primary outcomes

  1. Relative change in body weight

    Time frame: From baseline (week 0) to week 80

    Measured as percentage change.

Secondary outcomes

  1. Relative change in body weight in women

    Time frame: From baseline (week 0) to week 80

    Measured as percentage change.

  2. Number of participants who achieve greater than or equals (≥) 20% weight reduction

    Time frame: From baseline (week 0) to week 80

    Measured as count of participants.

  3. Number of participants who achieve ≥ 25% weight reduction

    Time frame: From baseline (week 0) to week 80

    Measured as count of participants.

  4. Number of participants who achieve ≥ 30% weight reduction

    Time frame: From baseline (week 0) to week 80

    Measured as count of participants.

  5. Number of participants who achieve BMI < 30 kg/m^2

    Time frame: From baseline (week 0) to week 80

    Measured as count of participants.

  6. Number of participants who achieve normal body mass index (BMI) (18.5 kilograms per meter square (kg/m^2) less than or equal to (≤ ) BMI < 25 kg/m^2)

    Time frame: From baseline (week 0) to week 80

    Measured as count of participants.

  7. Change in waist circumference

    Time frame: From baseline (week 0) to week 80

    Measured as centimeter (cm).

  8. Change in systolic blood pressure

    Time frame: From baseline (week 0) to week 80

    Measured as millimeters of mercury (mmHg).

  9. Ratio to baseline in C-reactive protein (CRP)

    Time frame: From baseline (week 0) to week 80

    Measured as ratio.

  10. Ratio to baseline in lipids: non-high density lipoprotein (HDL) cholesterol

    Time frame: From baseline (week 0) to week 80

    Measured as ratio.

  11. Ratio to baseline in lipids: triglycerides

    Time frame: From baseline (week 0) to week 80

    Measured as ratio.

  12. Ratio to baseline in lipids: HDL

    Time frame: From baseline (week 0) to week 80

    Measured as ratio.

  13. Change in impact of weight on quality of life-lite for clinical trials (IWQOL-Lite-CT) physical function score

    Time frame: From baseline (week 0) to week 80

    Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Physical function score ranges from 0 to 100, with higher scores indicating better levels of functioning.

  14. Change in short form (SF)-36v2 physical function

    Time frame: From baseline (week 0) to week 80

    Measured as score on a scale. The SF-36v2 acute measures health-related quality of life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 acute scores are norm-based scores, i.e. transformed to a scale where the 2009 United States general population has a mean of 50 and a standard deviation of 10. Physical functioning score ranges from 19.0-57.6, with higher scores indicating better functional health and well-being.

  15. Change in IWQOL-Lite-CT physical function for subgroup with poor physical functioning at baseline (according to patient global impression of status [PGI-S])

    Time frame: From baseline (week 0) to week 80

    Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Physical function score ranges from 0 to 100, with higher scores indicating better levels of functioning. PGI-S at baseline is used to define the subgroup with "poor" physical function in IWQOL-Lite-CT.

  16. Change in SF-36v2 physical function for subgroup with poor physical functioning at baseline (according to PGI-S)

    Time frame: From baseline (week 0) to week 80

    Measured as score on a scale. SF-36v2 acute measures HRQOL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 acute scores are norm-based scores, i.e. transformed to a scale where the 2009 United States general population has a mean of 50 and a standard deviation of 10. Physical functioning score ranges from 19.0-57.6, with higher scores indicating better functional health and well-being. PGI-S at baseline is used to define the subgroup with "poor" physical function in SF-36V2.

  17. Number of participants who achieve ≥ 5% weight reduction

    Time frame: From baseline (week 0) to week 80

    Measured as count of participants.

  18. Number of participants who achieve ≥ 10% weight reduction

    Time frame: From baseline (week 0) to week 80

    Measured as count of participants.

  19. Number of participants who achieve ≥ 15% weight reduction

    Time frame: From baseline (week 0) to week 80

    Measured as count of participants.

  20. Change in waist to height ratio

    Time frame: From baseline (week 0) to week 80

    Measured as ratio.

  21. Change in waist to hip ratio

    Time frame: From baseline (week 0) to week 80

    Measured as ratio.

  22. Number of participants with reduction in weight category

    Time frame: From baseline (week 0) to week 80

    Measured as count of participants. Reduction in weight categories: underweight, BMI < 18.5 kg/m^2; normal weight 18.5 kg/m^2 ≤ BMI < 25 kg/m^2; overweight 25 kg/m^2 ≤ BMI < 30 kg/m^2; obesity class I 30 kg/m^2 ≤ BMI < 35 kg/m^2; obesity class II 35 kg/m^2 ≤ BMI < 40 kg/m^2; obesity class III BMI ≥ 40 kg/m^2.

  23. Change in diastolic blood pressure

    Time frame: From baseline (week 0) to week 80

    Measured as mmHg.

  24. Ratio to baseline in lipids: total cholesterol

    Time frame: From baseline (week 0) to week 80

    Measured as ratio.

  25. Ratio to baseline in lipids: low-density lipoprotein (LDL) cholesterol

    Time frame: From baseline (week 0) to week 80

    Measured as ratio.

  26. Ratio to baseline in lipids: very low-density lipoprotein (VLDL) cholesterol

    Time frame: From baseline (week 0) to week 80

    Measured as ratio.

  27. Ratio to baseline in lipids: free fatty acids

    Time frame: From baseline (week 0) to week 80

    Measured as ratio.

  28. Change in control of eating questionnaire (CoEQ): craving control score

    Time frame: From baseline (week 0) to week 80

    Measured as score on a scale. CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the craving control subscale, the subscale score is reversed so that a higher score represents a greater level of craving control.

  29. Change in CoEQ: positive mood score

    Time frame: From baseline (week 0) to week 80

    Measured as score on a scale. CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the Positive Mood subscale, item 6 'How anxious have you felt?' is reversed.

  30. Change in CoEQ: craving for sweets score

    Time frame: From baseline (week 0) to week 80

    Measured as score on a scale. CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the craving sweets food subscale, higher score represents a greater level of craving.

  31. Change in CoEQ: craving for savoury score

    Time frame: From baseline (week 0) to week 80

    Measured as score on a scale. CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the craving savoury food subscale, higher score represents a greater level of craving.

  32. Change in CoEQ: hunger score

    Time frame: From baseline (week 0) to week 80

    Measured as score on a scale. CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the hunger subscale, higher score represents a greater level of craving.

  33. Change in CoEQ: satiety score

    Time frame: From baseline (week 0) to week 80

    Measured as score points. CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the satiety subscale, higher score represents a greater level of craving.

  34. Change in IWQOL-Lite-CT: physical score

    Time frame: From baseline (week 0) to week 80

    Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Physical score ranges from 0 to 100, with higher scores indicating better levels of functioning.

  35. Change in IWQOL-Lite-CT: psychosocial score

    Time frame: From baseline (week 0) to week 80

    Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Psychosocial score ranges from 0 to 100, with higher scores indicating better levels of functioning.

  36. Change in IWQOL-Lite-CT: total score

    Time frame: From baseline (week 0) to week 80

    Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Total score ranges from 0 to 100, with higher scores indicating better levels of functioning.

  37. Change in SF-36v2 health survey acute: physical component summary score

    Time frame: From baseline (week 0) to week 80

    Measured as score on a scale. The SF-36v2 acute measures HRQOL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 acute scores are norm-based scores, i.e. transformed to a scale where the 2009 United States general population has a mean of 50 and a standard deviation of 10. The physical component summary score ranges from 6.1-79.7, with higher scores indicating better functional health and well-being.

  38. Change in SF-36v2 health survey acute: mental component summary

    Time frame: From baseline (week 0) to week 80

    Measured as score on a scale. The SF-36v2 acute measures HRQOL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 acute scores are norm-based scores, i.e. transformed to a scale where the 2009 United States general population has a mean of 50 and a standard deviation of 10. The mental component summary score ranges from -3.8-78.7, with higher scores indicating better functional health and well-being.

  39. Number of treatment emergent adverse events (TEAEs)

    Time frame: From baseline (week 0) to week 80

    Measured as count of events.

  40. Number of treatment emergent serious adverse events (TESAEs)

    Time frame: From baseline (week 0) to week 80

    Measured as count of events.

Sponsors and collaborators

Lead sponsor

Novo Nordisk A/S

Industry

Registry information

Official study title

Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c. (CagriSema s.c.) Once Weekly for Weight Management and Long-term Weight Maintenance in Participants With Obesity

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
Jun 9, 2025
Registry last updated
Jul 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.